Lari­mar to re­spond to FDA this quar­ter on 15-month clin­i­cal hold of PhI Friedre­ich's atax­ia drug

More than a year af­ter the FDA clamped down on Lari­mar Ther­a­peu­tics with a clin­i­cal hold on its lead drug, the biotech thinks it has a way to get that lift­ed — and an an­swer could come next quar­ter if all goes to plan.

Amid a 15-month set­back, the biotech plans on fil­ing a com­plete re­sponse to the FDA’s con­cerns over its drug, CTI-1601, some­time this quar­ter, which is sup­posed to elic­it an an­swer from the agency with­in 30 days, per the reg­u­la­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER